Scientist-Clinical Pharmacology, Modeling and Simulation - South San Francisco, CA | Biospace
Get Our FREE Industry eNewsletter

Scientist-Clinical Pharmacology, Modeling and Simulation


South San Francisco, CA
Posted Date:
Position Type:
Full time
Job Code:
Required Education:
Bachelors Degree
Areas of Expertise Desired:

Job Description

The Scientist will serve as a PK/PD modeler (ie, pharmacometrican) to support Amgen Development and Translational Sciences programs across therapeutic areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.


Perform PK/PD analyses for small and large molecules from early to late drug development phase using state of the art modeling and simulation (M&S) techniques

Develop mechanistic models for translational biomarkers

Perform meta-analysis using literature data

Participate in cross-functional project teams and provide scientific input for dose selection and PK/PD study designs using M&S

Contribute to clinical pharmacology strategy for the program(s) and implement project (M&S) plan

Write PK/PD reports and contribute to the summary documents for regulatory submissions


Basic Qualifications:

Doctorate degree or anticipated graduation by September 2017


Master's degree and 4 years of scientific experience


Bachelor's degree and 6 years of scientific experience

Preferred Qualifications:

PhD in Pharmacokinetics, Pharmaceutical Sciences, Engineering, Statistics or related fields with equivalent professional degrees (e.g. MD, PharmD)

1+ years industry experience in PK/PD modeling / pharmacometrics of small molecules and/or biologics

Proficiency in modeling software (e.g. NONMEM, R/S-Plus, or MATLAB)

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.